Multidrug-resistant pathogens

Currently, the most common commercial application for lantibiotics is as a preservative in the food industry to combat food-home pathogens and spoilage bacteria, but many other uses are under active investigation. Duramycin has been shown to increase chloride transport in nasal epithelial cells of cystic fibrosis patients (13), which in turn increases the fluidity of mucus in the lungs and airway and decreases the patient s susceptibility to infections. Furthermore, several lantibiotics have shown potent activities against multidrug resistant pathogenic bacterial strains. Combined with the development of new techniques to alter the structures of lantibiotics, the future will likely see detailed SAR studies that may result in improved variants. 

Ma, Z., Clark, R. F., and Or, Y. (1999). Design, synthesis, and characterization of ABT-773 A novel ketolide highly active against multidrug-resistant pathogens. Presented at 39th Intersci. Conf. Antimicrob. Agents Chemother. (Sept. 26-29, San Franeisco). Abstr. No. 2133. 

Resistance factors, particularly those carried on mobile elements, can spread rapidly within human and animal populations. Multidrug-resistant pathogens are mobile on a local and global scale, with newly introduced pathogens spreading rapidly in susceptible hosts. Antibiotic resistance patterns may vary locally and regionally, hence... 

Martin-Loeches 1, Diaz E, Valles J. Risks for multidrug-resistant pathogens in the ICU. Curr Opin Crit Care. 2014 20(5) 516-24. 

The advent of multidrug resistant strains of Mycobacterium tuberculosis (MDR-TB) has led to increased fears of untreatable infections by serious pathogens. Rifampicin, streptomycin and, occasionally, the quinolones are drugs used in the treatment of mycobacterial infections and resistance to those agents is as described previously. There... 

The continuous increase of antibiotic resistance, including the emergence of multidrug resistance in common pathogens, has created an urgent need for antibiotics with novel mechanisms of action. PDF, an essential metallopro-tease that removes the V-formyl group of all newly synthesised bacterial... 

Jason Kindrachuk is a postdoctoral fellow at the University of British Columbia (UBC) in the laboratory of Professor R. E. W. Hancock. Jason received his Ph.D. from the University of Saskatchewan in 2007 where his research focused on host and pathogen sensory systems. During his study he specially focused on TLR-9 receptor—ligand interactions and the interactions between host defense peptides and the PhoPQ two-component sensory system of Salmonella typhimurium. In 2008 Jason received the Canadian Cystic Fibrosis Foundation Kin Canada Fellowship for his research in the area of alternative therapies for treatment of antibiotic- and multidrug-resistant bacteria. Currently his research is focused on the investigation of structure-activity relationships amongst natural and synthetic host defense peptides from the perspective of associated immunomodulatory activities and as well as vaccine formulation strategies. 

Berberis fremontii, B beridaceae Ang. of N American folk medicine/it acts by reversing multidrug resistance, as a multidrug pump inhibitor of the human pathogen, Stc hylococcus aureus, thus acting synergistically with the plant antibiotics... 

The overwhelming majority of semisynthetic beta-lactam antibiotics, the penicillins and cephalosporin, currently available to physicians trace their origins to the intense research effort devoted to this field several decades ago. The emergence of pathogens resistant to those antibiotics has led some laboratories to revisit this field. The modified cephalosporin ceftobiprole (220), a compound with a rather complex extended side chain, has shown activity in the clinic against some strains of multidrug resistant bacteria. The synthesis starts with the well-precedented acylation of the of the cephalosporin (215), available in several steps from the commercially available 7-acetoxy cephalosporanic acid, with the activated... 

---